Chronic glutathione depletion is documented in HIV/AIDS (where low GSH correlates with disease progression), Parkinsons disease (substantia nigra GSH levels are 40% lower than controls), non-alcoholic fatty liver disease, cystic fibrosis, and acute respiratory distress syndrome
Treatment with zVAD-FMK, Necrostatin-1, and Ferrostatin-1 mitigated pathological cardiac remodeling, reduced apoptosis and necroptosis-mediated myocardial injury, alleviated mitochondrial dysfunction, and improved cardiac function in post-MI rats
Acute symptoms such as fatigue may improve relatively quickly, whereas neurological symptoms like paraesthesia (pins and needles) or cognitive difficulties typically require longer treatment courses
Although giving glutathione as a supplement hasnt been proven to increase levels because supplements tend to be inactivated by the digestive system, certain nutrients can help boost glutathione production
Matching vial size to protocol length Because doses per vial follows directly from vial mass and target dose, sizing a vial (or vials) to a planned protocol length is a matter of working the formula backward: Total mg needed = number of planned doses dose size (mg) Worked example
